D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data

  title={D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data},
  author={David Mataix-Cols and Lorena Fern{\'a}ndez de la Cruz and Benedetta Monzani and David Rosenfield and Erik Andersson and Ana P{\'e}rez-Vigil and Paolo Frumento and Rianne A de Kleine and JoAnn Difede and Boadie W. Dunlop and Lara J. Farrell and Daniel A. Geller and Maryrose A. Gerardi and Adam John Guastella and Stefan G. Hofmann and Gert-Jan Hendriks and Matt Kushner and Francis S. Lee and Eric J. Lenze and Cheri A. Levinson and Harry McConnell and Michael W. Otto and Jens Plag and Mark H. Pollack and Kerry J. Ressler and Thomas L. Rodebaugh and Barbara O. Rothbaum and Michael S. Scheeringa and Anja Siewert-Siegmund and Jasper A. J. Smits and Eric A. Storch and Andreas Str{\"o}hle and Candyce D. Tart and David F. Tolin and Agnes van Minnen and Allison M. Waters and Carl F. Weems and Sabine Wilhelm and Katarzyna Wyka and Michael Davis and Christian P. R{\"u}ck and Margaret Altemus and Page Lyn Anderson and Judith Cukor and Claudia Finck and Gary R. Geffken and Fabian Golfels and Wayne K. Goodman and Cassidy A. Gutner and Isobel Heyman and Tanja Jovanovi{\'c} and Adam B. Lewin and Joseph P H Mcnamara and Tanya K. Murphy and Seth D. Norrholm and Paul D. Thuras},
  journal={JAMA Psychiatry},
Importance Whether and under which conditions D-cycloserine (DCS) augments the effects of exposure-based cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders is unclear. Objective To clarify whether DCS is superior to placebo in augmenting the effects of cognitive behavior therapy for anxiety, obsessive-compulsive, and posttraumatic stress disorders and to evaluate whether antidepressants interact with DCS and the effect of potential moderating… 

Figures and Tables from this paper

D-cycloserine augmentation of behavior therapy for anxiety and obsessive-compulsive disorders: A meta-analysis

The finding that study quality was inversely related to the reported effect sizes underlines the importance of high quality primary research in order to avoid over-estimation of treatment effects in clinical psychology.

Neurocognitive mechanisms of d-cycloserine augmented single-session exposure therapy for anxiety

Findings highlight a neurocognitive mechanism by which d-cycloserine may exert its augmentative effects on psychological treatment and bring forward a marker that may help understand and facilitate future development of adjunct treatments with CBT for anxiety disorders.

d-Cycloserine-Augmented Behavior Therapy for Body Dysmorphic Disorder: A Preliminary Efficacy Trial

Cognitive behavioral therapy (CBT) is the leading psychotherapeutic treatment for body dysmorphic disorder (BDD), yet not all patients improve. To address the treatment response gap, CBT may be

Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)

SSRI/clomipramine in combination with CBT/ERP is associated with the optimal response compared to each treatment alone or to other treatments, and the role of pharmacogenomics could become preponderant in the coming years.

N-methyl-d-aspartate Partial Agonist Enhanced Intensive Cognitive-Behavioral Therapy of Panic Disorder in Adolescents

This study examined the feasibility and acceptability of the use of DCS to augment intensive CBT for PD in adolescents and provides initial support for a more extensive study ofDCS augmentation of CBT among adolescents with PD.

Ketamine Augmentation of Exposure Response Prevention Therapy for Obsessive-compulsive Disorder.

The theory that NMDAR modulation might directly promote the therapeutic mechanisms involved in exposure and the possibility that ketamine plasticity enhancement might potentiate extinction-based psychotherapy in the treatment of OCD are described.

The Psychopharmacology of Obsessive-Compulsive Disorder: A Preclinical Roadmap

A significant proportion of patients with obsessive-compulsive disorder (OCD) do not achieve remission with current treatments, indicating the need for innovations in psychopharmacology for the disorder.



D-Cycloserine vs Placebo as Adjunct to Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder and Interaction With Antidepressants: A Randomized Clinical Trial.

The findings suggest that antidepressants may interact with DCS to block its facilitating effect on fear extinction, and use of DCS may be a promising CBT augmentation strategy but only in antidepressant-free patients with OCD.

D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis.

D-Cycloserine appears to be an effective augmentation agent that enhances the effects of behavioral therapy in the treatment of anxiety disorders and no evidence of an effect of dose number, dose timing, or dosage of D-cycloserine on reported efficacy in the ranges studied is found.

A Preliminary Study of D-Cycloserine Augmentation of Cognitive-Behavioral Therapy in Pediatric Obsessive-Compulsive Disorder

D-cycloserine augmentation in behavioral therapy for obsessive-compulsive disorder: a meta-analysis

D-cycloserine augmentation may enhance the efficacy of ERP therapy in reducing the symptomatic severity of OCD patients, especially at early stage of the treatment; therefore, DCS augmentation could possibly reduce treatment cost, reduce treatment drop and refusal rate, and help to improve access to the limited number of experienced therapists.

Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder.

Data provide support for the use of D-cycloserine as an augmentation of behavior therapy for OCD and extend findings in animals and other human disorders suggesting that behavior therapy acts by way of long-term potentiation of glutamatergic pathways and that the effects of behavior Therapy are potentiated by an NMDA agonist.

Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders.

This systematic review aimed to investigate the effects of adding d-cycloserine (DCS) to cognitive and behavioural therapies by synthesising data from relevant randomised controlled trials and following the guidelines recommended by Cochrane.

Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.

The pilot data provide preliminary support for the use of short-term dosing of d-cycloserine as an adjunctive intervention to exposure therapy for SAD.

D-cycloserine does not enhance exposure–response prevention therapy in obsessive–compulsive disorder

The present results fail to support the use of D-cycloserine with exposure and response prevention therapy for adult obsessive–compulsive disorder and are the first to explore this question.

A Randomized Controlled Trial of D-Cycloserine Enhancement of Exposure Therapy for Social Anxiety Disorder